

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---|--|--------------------|-------------------------------|--|--|--|----------------------|---|--|
| Abacavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | Yes | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Abacavir + dolutegravir + lamivudine (Triumeq®) | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | Yes | No | BHIVA Guidelines | Hospital only prescribing (Red) | NHS England Policy: B06/P/b HARS Dataset |
| Abacavir and lamivudine (Kivexa) | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | Yes | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Abatacept | Rheumatoid arthritis (after failure of DMARDs and anti-TNF) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA195 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA195 |
| Abatacept | Rheumatoid arthritis (after failure of conventional DMARD) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA280 & local policy | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA280 |
| Abatacept | Juvenile arthritis | NHS England | Non tariff | Not for primary care prescribing | Yes | No | | Hospital only prescribing (Red) | NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d |
| Abatacept | Paediatric indications (where adult TA available) | NHS England | Non tariff | Not for primary care prescribing | Yes | No | TA195 & 280 | Hospital only prescribing (Red) | AS PER ADULT TA'S (TA195, TA280) |
| Abciximab | Prevention MI during PCTA | CCG | In tariff | Not for primary care prescribing | Yes | No | TA47 & CG94 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA47 http://www.nice.org.uk/guidance/CG94 |
| Abiraterone | Metastatic castration resistant prostate cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | Yes | No | TA 259 or CDF | Hospital only prescribing (Red) | TA259 (SEE ALSO SSC1438) CDF POLICY - BOTH: ONLY IN ENZALUTAMIDE NAÏVE PATIENTS |
| Acamprosate | Alcohol misuse | PH Commissioned | In tariff | Primary care prescribing recharged to Commissioner | Yes | No | CG115 | No shared care. Specialist recommendation and directions if continued by GP | http://www.nice.org.uk/guidance/cg115 |
| ACE inhibitors | Cor pulmonale | CCG | In tariff | Not commissioned | N/A | No | CG101 | NICE DO NOT DO | |
| ACE inhibitors in combination with Angiotensin II antagonists | All indications | CCG | In tariff | Not commissioned | N/A | No | CG127 | Not recommended for use (Double Red) | http://publications.nice.org.uk/hypertension-cg127 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------|--|--------------|-------------------------------|--|--|--|---|---|---|
| Acetretin | Psoriasis | CCG | In tariff | Not for primary care prescribing | Yes | No | CG153 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/cg153 |
| Acidinium inhaler | COPD | CCG | In tariff | Prescribing in line with local formulary | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | http://www.nice.org.uk/advice/esnm8/chapter/Overview |
| Adalimumab | Rheumatoid arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA130 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA130 |
| Adalimumab | Ankylosing spondylitis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA143 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA143 |
| Adalimumab | Psoriasis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA146 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA146 |
| Adalimumab | Crohns | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA187 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA187 |
| Adalimumab | Rheumatoid arthritis (after failure of anti-TNF) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA195 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA195 |
| Adalimumab | Psoriatic arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA199 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA199 |
| Adalimumab | Ulcerative colitis (moderate to severe) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | TA329 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/ta329 |
| Adalimumab | Axial spondylarthropathy | CCG | Non tariff. Subject to audit | Not for primary care prescribing | Yes | No | Local policy & pathway | Hospital only prescribing (Red) | TAG |
| Adalimumab | Second line anti-TNF post Etanercept in ankylosing spondylitis, psoriatic arthritis or rheumatoid arthritis where IBD developed during treatment | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | Local policy & pathway | Hospital only prescribing (Red) | |
| Adalimumab | Paediatric indications where adult TA available & Juvenile Arthritis | NHS England | Non tariff | Not for primary care prescribing | | No | As per adult TA's (TA130, TA143, TA146, TA187, TA199) | Hospital only prescribing (Red) | Transfer to adult care upper limit 19th birthday. NICE audit |
| Adalimumab | Juvenile arthritis | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Interim Policy: B03/Ps/a. Transfer to adult care upper limit 19th birthday. NICE audit |
| Adalimumab | Uveitis | NHS England | Not routinely commissioned | Not for primary care prescribing | No | No | As per IFR approval | Not routinely commissioned | Not routinely commissioned - policy in progress |
| Adalimumab | Hidradenitis Suppurativa | NHS England | Not routinely commissioned | Not for primary care prescribing | No | No | As per IFR approval | Not routinely commissioned | Not routinely commissioned - policy in progress |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------|---|--------------|--------------------------------------|----------------------------------|--|--|-----------------------------------|---|---|
| Adalimumab | Behcet's | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | |
| Adefovir | Viral Hepatitis B&C & Respiratory Syncytial Virus | NHS England | Not routinely commissioned | Not for primary care prescribing | No | No | CG185 | Not recommended for use (Double Red) | Not routinely commissioned (CG185) |
| ADHD drug treatment | Children & adolescents first line use | CCG | Not commissioned | Not commissioned | No | No | CG72 | NICE DO NOT DO | |
| ADHD drug treatment | Use in Pre-school children | CCG | Not commissioned | Not commissioned | No | No | CG72 | NICE DO NOT DO | |
| Afatinib | NSCLC | NHS England | Non tariff | Not for primary care prescribing | | No | TA 310 & SCC1421 | Hospital only prescribing (Red) | NICE audit |
| Aflibercept | wet AMD | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | Yes | No | TA294 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA294 |
| Aflibercept | Macular oedema (retinal vein occlusion) | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | Yes | No | TA305 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA305 |
| Aflibercept | Diabetic Macular oedema | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | Yes | No | TA346 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/ta346 |
| Aflibercept | wet AMD in patients requiring >8 injections Ranibizumab per eye per year | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | Yes | No | TAG | Hospital only prescribing (Red) | Under review |
| Aflibercept | wet AMD in patients intolerant to Ranibizumab | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | Yes | No | TA294 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA294 |
| Aflibercept | wet AMD in patients inadequate response to Ranibizumab | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | Yes | No | TA294 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA294 |
| Aflibercept | All other indications, sequential or combination therapy | CCG | Not commissioned | Not for primary care prescribing | No | No | TAG | Not recommended for use (Double Red) | |
| Aflibercept | Cancer | CDF | CDF | Not for primary care prescribing | No | No | CDF policy | CDF | SACT & CDF national audit |
| Aflibercept | Metastatic colorectal cancer | NHS England | Not commissioned | Not commissioned | No | No | TA 307 | NICE DO NOT DO | |
| Agalsidase alfa and beta | Fabry's disease | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Hospital only prescribing (Red) | Highly specialised database |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------------------------|--|--------------|-------------------------------|----------------------------------|--|--|--|---|--|
| Agomelatine | Major Depressive Episodes | CCG | Not commissioned | Not commissioned | No | No | TA231 MHRA | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA231 |
| Aldesleukin | Cancer | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | SACT |
| Alemtuzumab | Multiple sclerosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA312 | Hospital only prescribing (Red) | Only when prescribed in specialist centre |
| Alemtuzumab | CLL | NHS England | Non tariff | Not for primary care prescribing | | No | Trust guidelines: (only if provided at zero drug cost) | Hospital only prescribing (Red) | Trust guidelines |
| Alemtuzumab | Pre-transplant immunosuppression | NHS England | Non tariff | Not for primary care prescribing | | No | Trust guidelines: (only if provided at zero drug cost) | Hospital only prescribing (Red) | Trust guidelines |
| Alendronate & Vitamin D combination | Secondary prevention osteoporotic fragility fractures in postmenopausal women | CCG | In tariff | Not commissioned | No | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Alendronic Acid | Secondary or Primary prevention osteoporotic fragility fractures in postmenopausal women | CCG | In tariff | Commissioned | N/A | No | TA160 & TA161 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA161 http://www.nice.org.uk/guidance/TA160 |
| Alfacalcidol | Preparation for hyperparathyroidectomy | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Alglucosidase alfa | Pompe Disease | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Hospital only prescribing (Red) | Highly specialised database |
| Alipogene Tiparvovec | Lipoprotein lipase deficiency | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Aliskiren | Essential hypertension | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | CG127 |
| Alisporivir | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Alitretinoin | Severe refractory chronic hand eczema | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA177 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA177 |
| Alpha blockers | Cor pulmonale | CCG | Not commissioned | Not commissioned | N/A | No | TAG | NICE DO NOT DO | |
| Alpha Mannosidase recombinant human | Alpha Mannosidase deficiency | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|----------------------------|--|--------------|---|----------------------------------|--|--|--|---|---|
| Alteplase | Acute ischaemic stroke | CCG | Commissioned. In tariff top up - no extra drug charge | Not for primary care prescribing | N/A | No | TA264 & TA52 & TA122 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA264 |
| Amantadine | Prophylaxis and Treatment of Influenza | CCG | Not commissioned | Not commissioned | N/A | No | TA168 | Not recommended for use (Double Red) | http://www.nice.org.uk/guidance/TA168 |
| Ambrisentan | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policies: A11/P/b & A11/PS/a |
| Amifampridine Phosphate | LEMS Neuromuscular disorder | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | NHS England Policy | As per IFR approval | NHS England Policy: D04/PS/a |
| Amikacin liposomal | Cystic Fibrosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Amiodarone | Supraventricular & ventricular arrhythmias | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | NICE CG under review. http://guidance.nice.org.uk/CG/Wave0/638 |
| Amphotericin B (liposomal) | Fungal infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust guidelines | Hospital only prescribing (Red) | Number of patients treated & proportion given for SPC indication within policy |
| Amprenavir | HIV infection | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | |
| Amrolifine | Fungal nail infections (topical) | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Anagrelide | Thrombocythaemia | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | Subject to funding transfer |
| Anakinra | Adult indications | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Anakinra | Paediatric indications | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Anakinra | Specialist Autoinflammatory disease | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Anakinra | Juvenile arthritis | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Interim Policy: B03/PS/a | Hospital only prescribing (Red) | NHS England Interim Policy: B03/PS/a |
| Anakinra | Cryopyrin-associated periodic syndrome | NHS England | Non tariff | Not for primary care prescribing | | No | Cryopyrin Associated Periodic Syndrome Service Specification | Hospital only prescribing (Red) | Highly specialised database and criteria |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---|---|--------------|-------------------------------|----------------------------------|--|--|---------------------|---|---|
| Anastrozole | Early oestrogen-receptor-positive breast cancer post-menopause. | CCG | In tariff | Commissioned | N/A | No | TA112 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA112 |
| Anidulafungin | Fungal infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Number of patients treated. Proportion given for SPC indications within policy |
| Antacid therapy | Long term frequent use | CCG | Not commissioned | Not commissioned | N/A | No | CG17 | NICE DO NOT DO | |
| Anti TNF | RA dose escalation above starting dose | CCG | Not commissioned | Not commissioned | N/A | No | TA130 | NICE DO NOT DO | |
| Anti TNF | Use in RA before DMARDs | CCG | Not commissioned | Not commissioned | N/A | No | CG79 | NICE DO NOT DO | |
| Antibiotic prophylaxis | Infective endocarditis & interventional procedure (dental/non dental) | CCG | Not commissioned | Not commissioned | N/A | No | CG64 | NICE DO NOT DO | |
| Antibiotics (oral for children) | Fever without apparent source | CCG | Not commissioned | Not commissioned | N/A | No | CG47 | NICE DO NOT DO | |
| Anticoagulant self monitoring (test strips) | INR monitoring | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Anti-D immunoglobulin | Rh-ve pregnant women | NHS England | Non tariff | Not for primary care prescribing | | No | TA156 | Hospital only prescribing (Red) | |
| Antihæmophilic Factor/von Willebrand Factor Complex | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | BCSH Guidelines |
| Antihistamines (oral) | Atopic eczema in children | CCG | Not commissioned | Not commissioned | N/A | No | CG79 | NICE DO NOT DO | |
| Antilymphocyte globulin | Aplastic anaemia, organ transplant | NHS England | Non tariff | Not for primary care prescribing | No | No | BCSH Guidelines | NICE DO NOT DO | BCSH Guidelines |
| Antioxidant Nutritional Supplements | All indications | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Antioxidants AMD | AMD | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Antipsychotics | ADHD (adults or children) | CCG | Not commissioned | Not commissioned | N/A | No | CG72 | NICE DO NOT DO | |
| Antipsychotics | Borderline personality disorder (medium to long term treatment) | CCG | Not commissioned | Not commissioned | N/A | No | CG78 | NICE DO NOT DO | |
| Antipsychotics | Combined use (except for short periods) | CCG | Not commissioned | Not commissioned | N/A | No | CG178 | NICE DO NOT DO | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------------------|---|--------------|-------------------------------|----------------------------------|--|--|--|---|---|
| Antipsychotics | Generalised Anxiety Disorder | CCG | Not commissioned | Not commissioned | N/A | No | CG113 | NICE DO NOT DO | |
| Antipsychotics (excluding Clozapine) | Schizophrenia | CCG | In tariff | Commissioned | N/A | Yes | CG82 | Shared care available (Amber) | http://guidance.nice.org.uk/CG82 |
| Antithrombin III | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | BCSH Guidelines |
| Antithymocyte immunoglobulin | Aplastic anaemia, organ transplant | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | BCSH Guidelines |
| Apixaban | For prevention of VTE after total hip or knee replacement in adults | CCG | In tariff | Hospital provides full course | N/A | No | TA245 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA245 |
| Apixaban | Prevention of stroke and systemic embolism (non-valvular atrial fibrillation) | CCG | In tariff | Pathway under review | N/A | No | TA275 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA275 |
| Apixaban | Treatment & prevention of PE and VTE | CCG | In tariff | Pathway under review | N/A | No | TA341 | Pathway under review | http://www.nice.org.uk/guidance/ta341 |
| Apomorphine | Parkinson's Disease | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local Homecare delivery arrangement |
| Apremilast | Psoriasis & Psoriatic arthritis | CCG | Not commissioned | Not commissioned | N/A | No | TA368 | NICE DO NOT DO | http://www.nice.org.uk/guidance/ta368 |
| Apremilast | Paediatric indications | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Aragam | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Aripiprazole | Schizophrenia | CCG | In tariff | Commissioned | N/A | Yes | CG82 | Shared care available (Amber) | http://guidance.nice.org.uk/CG82 |
| Aripiprazole | Schizophrenia 15 to 17 yrs | CCG | In tariff | Commissioned | N/A | Yes | TA213 | Shared care available (Amber) | http://guidance.nice.org.uk/TA213 |
| Aripiprazole | Bipolar disorder in adolescents | CCG | In tariff | Commissioned | N/A | Yes | TA292 | Shared care available (Amber) | http://guidance.nice.org.uk/TA292 |
| Aromatase inhibitors | Adjuvant hormonal treatment of early oestrogen receptor positive breast cancer in post menopausal women | CCG | In tariff | Commissioned | N/A | No | CG80 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/CG80 |
| Asfotase alpha | Hypophosphatasia | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | Specialist centre only |
| Asunaprevir with Daclatasvir | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | Specialist centre only |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|----------------------------|--|--|-------------------------------|--|--|--|--|---|---|
| Ataluren | Duchenne muscular dystrophy | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | Specialist centre only |
| Atazanavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Atomoxetine | ADHD | CCG | In tariff | Commissioned | N/A | Yes | TA98 | Shared care available (Amber) | http://guidance.nice.org.uk/TA98 |
| Autologous serum eye drops | Dry eye | Uncertain | In tariff | Not commissioned | N/A | No | | Not recommended for use (Double Red) | |
| Avanafil | Erectile dysfunction | CCG | In tariff | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Axitinib | RCC | NHS England or CDF | Non tariff | Not for primary care prescribing | No | No | TA 333 & CDF | Hospital only prescribing (Red) | SACT |
| Azacitidine | Myelodysplastic syndrome | NHS England | Non tariff | Not for primary care prescribing | No | No | TA218 | Hospital only prescribing (Red) | SACT |
| Azathioprine | UC/Crohns | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Azathioprine | Transplant immunosuppression | NHS England | Non tariff | Not for primary care prescribing but see notes | | No | Shared care to continue until formal repatriation agreed | See notes | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |
| Azilsartan | Hypertension | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Aztreonam Lysine | Cystic Fibrosis | NHS England when given by nebulisation or inhalation | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: A01/PS/a |
| Baclofen | Intrathecal Pump | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | NHS E policy |
| Basiliximab | Renal transplant | NHS England | Non tariff | Not for primary care prescribing | | No | TA85 & TA99 | Hospital only prescribing (Red) | NICE |
| BD Autoshields | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Becaplermin | Diabetic ulcers | CCG | In tariff | Not commissioned | N/A | No | TAG | Hospital only prescribing (Red) | |
| Bedaquiline fumarate | Multi drug resistant TB | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned - policy in progress | As per IFR approval | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------|--|--------------------|-------------------------------|----------------------------------|--|--|---|---|---|
| Belatacept | Renal transplant | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | NICE TA in progress- not routinely commissioned | As per IFR approval | NICE in progress |
| Belimumab | SLE | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | NICE TA in progress- not routinely commissioned | As per IFR approval | NICE in progress |
| Bendamustine | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | | No | TA216 or CDF | Hospital only prescribing (Red) | SACT & CDF national audit |
| Benzodiazepines | Ongoing treatment alcohol dependence | PH Commissioned | In tariff | Not commissioned | N/A | No | CG115 | NICE DO NOT DO | |
| Benzodiazepines | Panic disorder | CCG | Not commissioned | Not commissioned | N/A | No | CG113 | NICE DO NOT DO | |
| Beractant | Respiratory distress syndrome neonates | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Trust guidelines |
| Betaine | Homocystinuria | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Hospital only prescribing (Red) | Highly specialised database and criteria |
| Bevacizumab | Neurofibromatosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | As per National protocol (see NF2 service spec) | Hospital only prescribing (Red) | As per National protocol (see NF2 service spec) |
| Bevacizumab | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Bexarotene | CTCL | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Bilvarudin | STEMI | CCG | In tariff | Not for primary care prescribing | N/A | No | TA230 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA230 |
| Boceprevir | Viral Hepatitis C | NHS England | Non tariff | Not for primary care prescribing | | No | TA253 | Hospital only prescribing (Red) | NICE audit |
| Bortezomib | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | | No | TA129, TA228, TA311 CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Bosentan | Digital ulcers | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: A13/P/e |
| Bosentan | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: A11/PS/b |
| Bosutinib | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------------|--|-----------------|---------------------------------|--|--|--|---|---|---|
| Botulinum toxin A | Chronic migraine | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA260 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA260 |
| Botulinum toxin A | Achalasia and gastroparesis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Blepharospasm | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Chronic anal fissure | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Focal spasticity | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Hemifacial spasm | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Paediatric neurogenic and non neurogenic detrusor overactivity | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Oesophageal spasm and nutcracker oesophagus | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Overactive bladder/detrusor overactivity | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Spasmodic torticollis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Spasticity in neuromuscular conditions | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Botulinum toxin A | Focal spasticity in children | NHS England | Non tariff | Not for primary care prescribing | | No | Trust guidelines | Hospital only prescribing (Red) | |
| Botulinum toxin A | Intravesical use in spinal cord injury | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned for new patients | As per IFR approval | |
| Botulinum toxin A & B | All other indications | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Botulinum toxin B | Spasmodic torticollis where Botulinum A contra indicated | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy. Notification required |
| Brentuximab | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Buprenorphine | Substance dependence | PH Commissioned | In tariff | Primary care prescribing recharged to Commissioner | Yes | Yes | TA114 | Shared care available (Amber) | http://guidance.nice.org.uk/TA114 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---|---|-----------------|-------------------------------|---|--|--|--|---|---|
| Buprenorphine transdermal | Pain relief in patients with renal impairment (CKD 4) at risk opioid toxicity | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Bupropion | Smoking cessation in people with bipolar or psychosis | PH Commissioned | In tariff | Not commissioned | N/A | No | CG178 | NICE DO NOT DO | |
| Bupropion | Smoking cessation in people with bipolar or psychosis | PH Commissioned | In tariff | Not commissioned | N/A | No | CG178 | NICE DO NOT DO | |
| Busulfan | Chemotherapy in line with Network regimens | NHS England | Non tariff | Not for primary care prescribing | | No | Network Guidelines | Hospital only prescribing (Red) | SACT |
| C1 Esterase inhibitor | Hereditary angiodema - acute treatment only | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: B09/P/b |
| Cabazitaxel | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Cabozatinib | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Calcium & ergocalciferol prescribed generically | Osteoporosis prevention | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Calcium channel blockers | Cor pulmonale | CCG | Not commissioned | Not commissioned | N/A | No | CG101 | NICE DO NOT DO | |
| Canagliflozin | Combination therapy in management of Type 2 Diabetes | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA315 | GP Prescribing at request of Specialist (Green) | https://www.nice.org.uk/Guidance/TA315 |
| Canakinumab | Juvenile arthritis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned TA302 | As per IFR approval | |
| Canakinumab | Cryopyrin-associated periodic syndrome | NHS England | Non tariff | Not for primary care prescribing | | No | Cryopyrin Associated Periodic Syndrome Service Specification | Hospital only prescribing (Red) | Highly specialised database and criteria |
| Cannabis (all forms including Nabilone) | All indications | Uncertain | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Cannabis spray | Adjuvant moderate to severe spasticity in MS | Uncertain | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | NICE discontinued |
| Capecitabine | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA100, TA61, TA191 & SACT | Hospital only prescribing (Red) | SACT |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------------|---|--------------------|-------------------------------|----------------------------------|--|--|--------------------------------------|---|---|
| Carglumic acid | Urea cycle disorder | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Hospital only prescribing (Red) | Highly specialised database and criteria |
| Cartinine | Cartinine Deficiency | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Hospital only prescribing (Red) | Highly specialised database and criteria |
| Caspofungin | Fungal infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy |
| Catridecacog | Congenital factor XIII A-subunit deficiency | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Ceftriaxone | Cellulitis | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local pathway |
| Certolizumab | Rheumatoid arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA186 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA186 |
| Certolizumab | Rheumatoid arthritis (after failure of anti-TNF) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA195 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA195 |
| Certolizumab | Psoriatic arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy & pathway |
| Certolizumab | Axial spondylarthropathy | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy & pathway |
| Certolizumab Pegol | Paediatric indications | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Cetuximab | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | | No | TA145, TA176 or CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Chemotherapy | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | | No | Network guidelines/ NICE/ CDF policy | Hospital only prescribing (Red) | SACT |
| Chlorambucil | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | Network Guidelines | Hospital only prescribing (Red) | SACT |
| Chlorhexidine mouthwash | Prophylaxis infective endocarditis dental procedure | CCG | Not commissioned | Not commissioned | N/A | No | CG64 | NICE DO NOT DO | |
| Chondroitin | Osteoarthritis | CCG | Not commissioned | Not commissioned | N/A | No | CG59 | NICE DO NOT DO | |
| Ciclesonide inhaler | Asthma | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Ciclosporin | Rheumatic & Dermatological as per shared care | CCG | In tariff | Commissioned | Yes | Yes | TAG | Shared care available (Amber) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---------------|--|-----------------|-------------------------------|--|--|--|--|---|---|
| Ciclosporin | Transplant immunosuppression | NHS England | Non tariff | Not for primary care prescribing but see notes | | No | Shared care to continue until formal repatriation agreed | See notes | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |
| Cidofovir | CMV infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy |
| Cilostazol | Peripheral Arterial Disease | CCG | Not commissioned | Not commissioned | N/A | No | TA223 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA223 |
| Cinacalcet | Hyperparathyroidism - dialysis patients only | NHS England | Non tariff | Not for primary care prescribing | | No | TA117 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA117 |
| Ciprofloxacin | Anthrax Plague Tularemia exposure | PH Commissioned | In tariff | Commissioned according to national pathway | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Ciprofloxacin | Anthrax Plague Tularemia exposure | PH Commissioned | In tariff | Commissioned according to national pathway | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Cladribine | Multiple sclerosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | Specialist centre only |
| Cladribine | Pulmonary Langerhans histiocytosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | Specialist centre only |
| Cladribine | Cancer | NHS England | Non tariff | Not commissioned | | No | Network Guidelines | Hospital only prescribing (Red) | SACT |
| Clofarabine | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Clomethazole | Alcohol withdrawal | PH Commissioned | Not commissioned | Not commissioned | N/A | No | CG115 | NICE DO NOT DO | |
| Clomethazole | Alcohol withdrawal | PH Commissioned | Not commissioned | Not commissioned | N/A | No | CG115 | NICE DO NOT DO | |
| Clopidogrel | ACS without NSTEMI | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Clopidogrel | Prevention atherosclerotic events | CCG | In tariff | Commissioned | N/A | No | TA210 | Hospital & GP Prescribing (Double Green) | |
| Clopidogrel | Post elective PCI bare metal stent | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Clozapine | Schizophrenia | CCG | In tariff | Not for primary care prescribing | N/A | No | CG82 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/CG82 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|--|--|-------------------------------|----------------------------------|--|--|---|---|---|
| Cobicistat | HIV infection in combination with other antiretroviral drugs | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned - policy in progress | Hospital only prescribing (Red) | HARS dataset |
| Co-careldopa | Advanced Parkinson's Disease | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Co-Enzyme Q10 | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Colesevelam | Primary hypercholesterolaemia | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Colistimethate sodium | Non CF Bronchiectasis | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Colistimethate sodium | Cystic Fibrosis | NHS England when given by nebulisation or inhalation | Non tariff | Not for primary care prescribing | | No | TA276 & NHS England Policy | Hospital only prescribing (Red) | NICE audit TA276 & NHS England Policy: A01/PS/a |
| Collagenase | Dupuytren's contracture | CCG | Not commissioned | Not commissioned | N/A | No | NICE in progress | Not recommended for use (Double Red) | |
| Combination drugs | Various | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Conestat alfa | Hereditary angiodema - acute treatment only | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: B09/P/b |
| Coproxamol | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Corticosteroids (Topical) | Atopic eczema | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Corticosteroids for Adults (Inhaled) | Chronic asthma (adults) | CCG | In tariff | Commissioned | N/A | No | TA138 | Hospital & GP Prescribing (Double Green) | NICE advises least costly suitable product where recommended either in monotherapy or combination with LABA |
| Corticosteroids for Children (Inhaled) | Chronic asthma (children) | CCG | In tariff | Commissioned | N/A | No | TA131 | Hospital & GP Prescribing (Double Green) | NICE advises least costly suitable product where recommended either in monotherapy or combination with LABA |
| Cough & cold remedies | Over the counter preparations | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------|--|--------------|-------------------------------|---|--|--|--|---|---|
| COX II Inhibitors | Pain & inflammation in OA or RA | CCG | In tariff | Commissioned according to local pathway | N/A | No | CG79 | Hospital & GP Prescribing (Double Green) | |
| Crizotinib | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Cyclophosphamide | Chemotherapy in line with Network regimens | NHS England | Non tariff | Not for primary care prescribing | | No | Network Guidelines | Hospital only prescribing (Red) | SACT |
| Dabigatran | VTE prevention hip or knee surgery | CCG | In tariff | Hospital provides full course | N/A | No | TA157 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA157 |
| Dabigatran | VTE & PE treatment & prevention | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA327 | GP Prescribing at request of Specialist (Green) | https://www.nice.org.uk/guidance/ta327 |
| Dabigatran | Stroke & systemic embolism prevention in non-valvular AF | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA249 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA249 |
| Dabrafenib | Melanoma | NHS England | Non tariff | Not for primary care prescribing | | No | TA321 | Hospital only prescribing (Red) | SACT |
| Daclatasvir | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | NHS England | Not routinely commissioned | | | No | Not routinely commissioned - NICE TA in progress | As per IFR approval | HARS dataset |
| Danazol | Heavy menstrual bleeding | CCG | Not commissioned | Not commissioned | N/A | No | CG44 | NICE DO NOT DO | |
| Dapagliflozin | Type 2 Diabetes | CCG | In tariff | Commissioned | N/A | No | TA288 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA288 |
| Dapagliflozin | Triple therapy in T2DM with metformin & sulfonylurea | CCG | Not commissioned | Not commissioned | N/A | No | TA288 | NICE DO NOT DO | |
| Dapoxetine | For diagnosed premature ejaculation | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Darbepoetin | Cancer treatment induced anaemia | NHS England | Not routinely commissioned | Not for primary care prescribing | No | No | TA142 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA142 |
| Darbepoetin | Dialysis-induced anaemia | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | For all ESA, product with lowest procurement cost to be used. |
| Darbepoetin | Anaemia associated with renal failure in pre-dialysis patients | NHS England | Not routinely commissioned | Not for primary care prescribing | No | No | | Not recommended for use (Double Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------|--|--------------|-------------------------------|----------------------------------|--|--|---|---|---|
| Darunavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Dasatinib | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Decitabine | Cancer | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned (TA270) | As per IFR approval | |
| Deferasirox | Iron chelation in thalassaemia, sickle cell | NHS England | Non tariff | Not for primary care prescribing | | No | Policy in progress | Hospital only prescribing (Red) | Anaemia related to chronic iron overload for myelodysplastic syndrome CCG responsibility - under review |
| Deferiprone | Iron chelation in thalassaemia, sickle cell | NHS England | Non tariff | Not for primary care prescribing | | No | Policy in progress | Hospital only prescribing (Red) | Anaemia related to chronic iron overload for myelodysplastic syndrome CCG responsibility - under review |
| Defibrotide | Hepatic veno-occlusive disease | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy: B04/P/c | Hospital only prescribing (Red) | NHS England Policy: B04/P/c |
| Degarelix | Advanced hormone dependent prostate cancer | Uncertain | Not commissioned | Not commissioned | N/A | No | NICE in progress | Not recommended for use (Double Red) | |
| Delamanid | Multi drug resistant TB | NHS England | Not routinely commissioned | | | No | Not routinely commissioned - policy in progress | As per IFR approval | |
| Denosumab | Bone loss non-metastatic prostate cancer | CCG | Not commissioned | Not commissioned | N/A | No | TA194 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA194 |
| Denosumab | Primary prevention fractures postmenopausal women | CCG | In tariff | Commissioned | N/A | Yes | TA204 | Shared care available (Amber) | http://guidance.nice.org.uk/TA204 |
| Denosumab | Bone mets from solid tumours | CCG | In tariff | Under review | N/A | No | TA265 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA265 |
| Desferrioxamine | Iron chelation in thalassaemia, sickle cell | NHS England | Non tariff | Not for primary care prescribing | | No | Policy in progress | Hospital only prescribing (Red) | Anaemia related to chronic iron overload for myelodysplastic syndrome CCG responsibility - under review |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|------------------------------|--|--------------|--------------------------------------|---|--|--|----------------------------|---|---|
| Desloratadine | Antihistamine | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Dexamethasone implant | Macular oedema (retinal vein occlusion) | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA229 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA229 |
| Dexamethasone implant | Diabetic Macular oedema | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA349 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/ta349 |
| Dexamethasone implant | All other indications, sequential or combination therapy | CCG | Not commissioned | Not for primary care prescribing | N/A | No | TAG | Not recommended for use (Double Red) | |
| Dexamfetamine | ADHD | CCG | In tariff | Commissioned | Yes | No | TA98 | Shared care available (Amber) | http://guidance.nice.org.uk/TA98 |
| Dexamfetamine | ME | Uncertain | Not commissioned | Not commissioned | N/A | No | CG53 | NICE DO NOT DO | |
| Dexrazoxane | Anthracycline cardiotoxicity | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Dexrazoxane | Anthracycline extravasation | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Trust Guidelines |
| Dibotermin alfa | Acute tibia fractures | CCG | Non tariff. Notification and audit | Not for primary care prescribing | N/A | No | PAC policy | Hospital only prescribing (Red) | For TAG review 15-16 |
| Dibotermin alfa | Complex spinal surgery | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Didanosine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Dietary Supplements | Various | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Digoxin | Cor pulmonale | CCG | Not commissioned | Not commissioned | N/A | No | CG101 | NICE DO NOT DO | |
| Dimethyl fumarate | Multiple sclerosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA320 | Hospital only prescribing (Red) | Specialist centre only |
| Dipyridamole MR | Prevention arteriosclerotic events | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA210 | GP Prescribing at request of Specialist (Green) | |
| Dipyridamole MR with aspirin | Prevention arteriosclerotic events | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA210 | GP Prescribing at request of Specialist (Green) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------------|--|--------------------------|-------------------------------|--|--|--|---------------------------------|---|---|
| Disulfiram | Alcohol misuse | PH Commissioned | In tariff | Under review | N/A | Under review | | Under review | Requires recharge to PH if prescribed in primary care |
| Docetaxel | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA109, 101 & Network guidelines | Hospital only prescribing (Red) | SACT |
| Dolutegravir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy: B06/P/b | Hospital only prescribing (Red) | HARS dataset |
| Donepezil | Alzheimer's disease (mild to moderate) | CCG | In tariff | Commissioned | N/A | Yes | TA217 | Shared care available (Amber) | Product with lowest procurement cost to be used |
| Dornase alfa | Cystic fibrosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA 276 & NHS England Policy | Hospital only prescribing (Red) | TA276 & NHS England Policy: A01/PS/a |
| Dosulepin | Depression | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Doxazosin MR | Hypertension | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Doxorubicin (liposomal) | Ovarian cancer (advanced) & CDF | NHS England or CDF | Non tariff | Not for primary care prescribing | | No | TA91 or CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Doxycycline | Anthrax Plague Tularemia exposure | PH Commissioned | In tariff | Commissioned according to national pathway | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Doxycycline | Anthrax Plague Tularemia exposure | PH Commissioned | In tariff | Commissioned according to national pathway | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Dried Prothrombin | Licensed indications | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Drisapersen | Duchenne Muscular Dystrophy | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Dronedarone | AF non permanent | CCG | In tariff | Commissioned | Yes | Yes | TA197 | Shared care available (Amber) | http://guidance.nice.org.uk/TA197 |
| Duloxetine | Depression | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Duloxetine | Moderate to severe stress urinary incontinence | CCG | In tariff | Commissioned according to local pathway | Yes | Yes | TAG | Shared care available (Amber) | |
| Ecallantide | Hereditary angioedema - acute treatment only | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Eculizumab | aHUS | NHS England Central Team | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: E03/PS(HSS)/a Specialist centres only |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---|---|--------------------------|------------------------------------|---|--|--|---|---|--|
| Eculizumab | Paroxysmal nocturnal haemoglobinuria | NHS England Central Team | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Hospital only prescribing (Red) | NHS National Specialised Commissioning Team Service Specification. Specialist centres only |
| Efavirenz | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Eflornithine | Hirsutism | CCG | In tariff | Commissioned according to local pathway | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Efralococog alpha | Haemophilia A | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Eftrenonacog alpha | Haemophilia B | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Elena skin products | | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Eliglustat | Gaucher's disease | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | Highly specialised database and criteria |
| Elosulfase alfa | Mucopolysaccharidosis IVA | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned - policy in progress | As per IFR approval | |
| Eltrombopag | Chronic immune (idiopathic) thrombocytopenic purpura | CCG | Non tariff. Notification and audit | Not for primary care prescribing | N/A | No | TA293 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA293 |
| Eltrombopag | Thrombocytopenia in adult patients with chronic hepatitis C virus infection | CCG | Not commissioned | Not commissioned | N/A | No | PAC policy | Not recommended for use (Double Red) | |
| Elvitegravir | HIV infection in combination with other antiretroviral drugs | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned - policy in progress | As per IFR approval | |
| Elvitegravir with Cobicistat, Emtricitabine and Tenofovir (Stribild®) | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: B06/PS/a HARS dataset |
| Elvucitabine | HIV infection in combination with other antiretroviral drugs | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|----------------------------------|---|--------------------|-------------------------------|--|--|--|---|---|--|
| Emergency Hormonal Contraception | Contraception | PH Commissioned | In tariff | Primary care prescribing recharged to Commissioner | N/A | No | | Under review | Requires recharge to PH if prescribed in primary care |
| Empagliflozin | Combination therapy in management of Type 2 Diabetes | CCG | In tariff | Commissioned | N/A | No | TA336 | GP Prescribing at request of Specialist (Green) | http://www.nice.org.uk/guidance/ta336 |
| Emtricitabine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Emtricitabine and tenofovir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Enfuvirtide | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Entecavir | Hepatitis B | NHS England | Non tariff | Not for primary care prescribing | | No | TA153 & in progress | Hospital only prescribing (Red) | NICE audit |
| Enteral Nutrition | PEG & NG feeding | CCG | In tariff | Commissioned | N/A | No | | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/CG32 |
| Enzalutamide | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | | No | TA316 (see also SSC1439) CDFpolicy - both: only in abiraterone naïve patients | Hospital only prescribing (Red) | SACT & CDF national audit |
| Eplerenone | Second line therapy for heart failure patients intolerant to spironolactone | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Epoetin | Anaemia associated with renal failure in pre-dialysis patients | CCG | Not commissioned | Not for primary care prescribing | N/A | No | TAG | Not recommended for use (Double Red) | Under review |
| Epoetin (all variants) | Dialysis-induced anaemia | NHS England | Non tariff | Not for primary care prescribing | | No | Renal dialysis only including via outpatients and only as per NICE CG114 & Trust guidelines | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/CG114 Product with lowest procurement cost to be used (NICE CG 114) |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------------------------|---|--------------|-------------------------------|----------------------------------|--|--|--|---|---|
| Epoetin alfa or beta | Cancer treatment induced anaemia | NHS England | In tariff | Not for primary care prescribing | | No | TA323 | Hospital only prescribing (Red) | https://www.nice.org.uk/guidance/ta323 Use lowest acquisition cost product |
| Epoprostenol | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | NHS England Policy: A11/PS/b |
| Epratuzumab | SLE | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Eprodinate | Amyloidosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Eptifibatide | Prevention MI unstable angina | CCG | In tariff | Not for primary care prescribing | N/A | No | TA47 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA47 |
| Eptotermin | Complex spinal surgery | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Eribulin | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Erlotinib | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA162 TA 227 & in progress. NHSE letter | Hospital only prescribing (Red) | SACT |
| Escitalopram | Social anxiety disorder | CCG | Not commissioned | Not commissioned | N/A | No | CG159 | Not recommended for use (Double Red) | |
| Esomeprazole | All indications | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Etanercept or licensed biosimilar | Psoriasis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA103 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA103 |
| Etanercept or licensed biosimilar | Rheumatoid arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA130 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA130 |
| Etanercept or licensed biosimilar | Ankylosing spondylitis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA143 | hospital only prescribing (Red) | http://guidance.nice.org.uk/TA143 |
| Etanercept or licensed biosimilar | Rheumatoid arthritis (after failure of anti-TNF) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA195 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA195 |
| Etanercept or licensed biosimilar | Psoriatic arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA199 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA199 |
| Etanercept or licensed biosimilar | Axial spondyloarthritis (non-radiographic) | CCG | Not commissioned | Not commissioned | N/A | No | NICE in progress | Not recommended for use (Double Red) | |
| Etanercept or licensed biosimilar | Juvenile arthritis | NHS England | Non tariff | Not for primary care prescribing | | No | TA35 | Hospital only prescribing (Red) | NICE audit |
| Etanercept or licensed biosimilar | Paediatric indications (where adult TA available) | NHS England | Non tariff | Not for primary care prescribing | | No | As per Adult TA's (TA103, TA130, TA143, TA199) | Hospital only prescribing (Red) | NICE audit |
| Ethamsylate | Heavy menstrual bleeding | CCG | Not commissioned | Not commissioned | N/A | No | CG44 | NICE DO NOT DO | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------------------------|--|--------------|-------------------------------|---|--|--|----------------------------|---|--|
| Etidronate | Primary & Secondary prevention osteoporotic fragility fractures in postmenopausal women | CCG | In tariff | Commissioned | N/A | No | TA161 & TA160 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA161 http://www.nice.org.uk/guidance/TA160 |
| Etonogestrel or Ethinyloestradiol | Medium acting reversible contraception where oral and transdermal options are unsuitable | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Etoposide | Chemotherapy in line with Network regimens | NHS England | Non tariff | Not for primary care prescribing | | No | Network Guidelines | Hospital only prescribing (Red) | SACT |
| Etravirine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Everolimus | Tubular sclerosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Everolimus | Renal angiomyolipoma | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Everolimus | Cancer | CDF | CDF | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | SACT & CDF national audit |
| Evolocumab | Homozygous familial hypercholesterolemia | CCG | Not commissioned | Not commissioned | N/A | No | NICE in progress | Not recommended for use (Double Red) | |
| Evolocumab | Hyperlipidaemia and mixed dyslipidaemia | CCG | Not commissioned | Not commissioned | N/A | No | NICE in progress | Not recommended for use (Double Red) | |
| Exemestane | Adjuvant treatment of oestrogen-receptor-positive early breast cancer | CCG | In tariff | Commissioned | N/A | No | TA112 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/CG80 |
| Exemestane | Early oestrogen-receptor-positive breast cancer post-menopause. | CCG | In tariff | Commissioned | N/A | No | TA112 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA112 |
| Exenatide | Treatment of Type 2 diabetes, HbA1c ≥ 58mmol/mol (7.5%), BMI ≥35 kg/m ² | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/CG66 |
| Exenatide | Co-use with insulin under specified local criteria | CCG | In tariff | Commissioned according to local pathway | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | Local policy |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|---|--------------|-------------------------------|----------------------------------|--|--|-----------------------------|---|---|
| Exenatide prolonged release | Treatment of Type 2 diabetes, HbA1c \geq 58mmol/mol (7.5%), BMI \geq 35 kg/m ² | CCG | In tariff | Commissioned | N/A | No | TA248 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA248 |
| Ezetimibe & combination products | Hypercholesterolaemia | CCG | In tariff | Commissioned | N/A | No | TA132 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA132 |
| Factor VII VIII IX VIIa VIII Fc VIII inhibitor bypassing factor XIII | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | |
| Fampridine | Multiple sclerosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | NHS England Policy: D04/PS/d |
| Febuxostat | Hyperuricaemia intolerant to allopurinol | CCG | In tariff | Commissioned | N/A | No | TA164 | Hospital & GP Prescribing (Double Green) | http://www.nice.org.uk/guidance/ta164 |
| Fentanyl | 3rd line option breakthrough cancer pain | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Fentanyl | Breakthrough pain in cancer | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Fibrates | Primary prevention CVD | CCG | Not commissioned | Not commissioned | N/A | No | CG67 | NICE DO NOT DO | |
| Fibrin sealants | Haemostatic/tissue glue | CCG | In tariff | Not for primary care prescribing | N/A | No | | Hospital only prescribing (Red) | |
| Fibrinogen | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | |
| Fibroblast growth factor 1 gene therapy | Somatostatin analogue | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Fidaxomicin | Clostridium difficile infection (CDI) | CCG | In tariff | Commissioned | N/A | No | | GP Prescribing at request of Specialist (Green) | |
| Filgrastim | Neutropenia | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy Product with lowest acquisition cost to be used |
| Filgrastim | Barth Syndrome | NHS England | Non tariff | Not for primary care prescribing | | No | Highly specialised criteria | Hospital only prescribing (Red) | Highly specialised criteria |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------|--|--------------|--|----------------------------------|--|--|--|---|---|
| Filibuvir | Viral Hepatitis (B&C) & Respiratory Syncytial Virus | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Fingolimod | Multiple sclerosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA254 & NHS England Policy | Hospital only prescribing (Red) | TA254NHS England Policy: D04/P/b |
| Fish Oils | All indications | CCG | Not commissioned | Not commissioned | N/A | No | CG67, CG71, CG40 | NICE DO NOT DO | |
| Flavoxate | Overactive bladder in women | CCG | Not commissioned | Not commissioned | N/A | No | CG40 | NICE DO NOT DO | |
| Flebogamma | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Flebogammadif | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Fludarabine | CLL First line Monotherapy | NHS England | Not routinely commissioned | Not for primary care prescribing | No | No | TA119 Not routinely commissioned | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA119 |
| Fludarabine | CLL Second line | NHS England | Non tariff | Not for primary care prescribing | | No | TA29 | Hospital only prescribing (Red) | |
| Fluocinolone implant | Diabetic Macular oedema | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA301 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA301 |
| Fluocinolone implant | All other indications, sequential or combination therapy | CCG | Not commissioned | Not for primary care prescribing | N/A | No | TAG | Not recommended for use (Double Red) | |
| Fluticasone & Vilanterol | COPD or asthma | CCG | Not commissioned | Not for primary care prescribing | N/A | No | TAG | Not recommended for use (Double Red) | |
| Folic Acid | Secondary prevention MI | CCG | Not commissioned | Not commissioned | N/A | No | CG48 | NICE DO NOT DO | |
| Fomepizole | Poisoning | Uncertain | Commissioned in line with National Poisons Centre Guidance | Not for primary care prescribing | N/A | No | | Poisons Centre Prescribing Only | Local commissioner to be notified when used |
| Fondaparinux | Unstable angina/MI | CCG | In tariff | Not for primary care prescribing | N/A | No | CG92 | Hospital only prescribing (Red) | |
| Forigerimod acetate | SLE | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------|--|--------------|-------------------------------|----------------------------------|--|--|--|---|---|
| Fosamprenavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Foscarnet | CMV infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy |
| Fosphenytoin | Status epilepticus | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Fulvestrant | Locally advanced or metastatic breast cancer | NHS England | Not routinely commissioned | Not for primary care prescribing | No | No | TA239 Not routinely commissioned | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA239 |
| Fumaric acid ester | Psoriasis | CCG | In tariff | Not commissioned | N/A | No | TAG | Hospital only prescribing (Red) | |
| Gabapentin | Neuropathic Pain | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Galantamine | Alzheimer's disease (mild to moderate) | CCG | In tariff | Commissioned | N/A | Yes | TA217 | Shared care available (Amber) | http://guidance.nice.org.uk/TA217 |
| Galsufase | Mucopolysaccharidosis | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Hospital only prescribing (Red) | Highly specialised database and criteria |
| Gammagard | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Gammanorm | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Gammaplex | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Gamolenic Acid | All indications | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Gamunex | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Ganciclovir | CMV infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy |
| Ganetespi | Cancer | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | SACT |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------|---|--------------|---|----------------------------------|--|--|---------------------------------|---|---|
| Gefitinib | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA192 | Hospital only prescribing (Red) | SACT |
| Gemcitabine | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA116, TA25, Network guidelines | Hospital only prescribing (Red) | SACT |
| Gentamicin (nebulised) | Pseudomonas aeruginosa infection in non-CF bronchiectasis | CCG | In tariff | Not for primary care prescribing | N/A | Yes | TAG | Shared care available (Amber) | |
| Gevokizumab | Uveitis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Glatiramer | Multiple sclerosis | NHS England | Funded NHS England DH risk sharing scheme | Not for primary care prescribing | | No | TA32 & NHS England Policy | Hospital only prescribing (Red) | TA32 & NHS England Policy: D04/P/b |
| Glibenclamide | Type 2 Diabetes | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Gliclazide MR | Type 2 Diabetes | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| GlobiFer | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Glucosamine | All indications | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Gluten free products | Gluten sensitive enteropathies | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| GlycoPEGylated Factor IX | | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Glycoprotein IIb & IIIa | ACS | CCG | In tariff | Not for primary care prescribing | N/A | No | TA47 | Hospital only prescribing (Red) | |
| Glycopyrronium | Hyperhidrosis (severe) | CCG | Not commissioned | Not commissioned | N/A | No | PAC policy | Not recommended for use (Double Red) | |
| Glycopyrronium inhaler | COPD | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Golimumab | Psoriatic arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA220 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA220 |
| Golimumab | RA methotrexate naïve | CCG | Not commissioned | Not commissioned | N/A | No | TA224 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA224 |
| Golimumab | Moderate to severe ulcerative colitis- second line | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA329 | Hospital only prescribing (Red) | |
| Golimumab | Axial spondyloarthritis (non-radiographic) | CCG | Not commissioned | Not commissioned | N/A | No | NICE in progress | Not recommended for use (Double Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|--|--------------|---------------------------------|----------------------------------|--|--|--|---|---|
| Golimumab | Rheumatoid arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA225 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA225 |
| Golimumab | Ankylosing spondylitis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA233 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA233 |
| Golimumab | Paediatric indications | NHS England | Non tariff | Not for primary care prescribing | | No | As per adults TA's (TA220, TA233) | Hospital only prescribing (Red) | NICE audit |
| Goserelin | Endometriosis, pre-operative management uterine fibroids | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Goserelin | Prostate cancer | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Granulocyte-macrophage colony-stimulating factor (Leukine® - Import) | Antibody-positive pulmonary alveolar proteinosis | NHS England | Not routinely commissioned | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Grass Pollen Extract | Seasonal grass pollen allergy | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Under review |
| Heparin (LMW) | Ante-natal VTE prevention | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Not recommended for use (Double Red) | Under review |
| Heparin (LMW) | DVT Out of Hours | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | Under review |
| Heparin (LMW) | DVT prevention during flights | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Heparin (LMW) | Unstable angina/MI | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Under review |
| Heparin (LMW) | Where warfarin contra-indicated | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | Under review |
| Heparin (unfractionated) | SC use in pregnancy | CCG | In tariff | Under review | N/A | No | TAG | Under review | Under review |
| Heparinoid | All indications | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Herbal products | All indications | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Hizentra | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------|--|--------------|-------------------------------|----------------------------------|--|--|-----------------------------------|---|---|
| Homeopathic preparations | All indications | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Human Arginate | Hepatic porphyria | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Highly specialised criteria only | Highly specialised database |
| Hyal G-F 20 | Osteoarthritis | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Hyaluronate | Osteoarthritis | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Hydroxycarbamide | Sickle Cell disease | NHS England | In tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Hydroxycarbamide | Sickle Cell disease | NHS England | In tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Hydroxycarbamide | CML/Myeloproliferative disorders | NHS England | In tariff | Not for primary care prescribing | Yes | Yes | | Shared care to continue until repatriated to hospital | |
| Ibandronic acid | Reduction of bone damage in bone mets in breast cancer | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Ibandronic acid | Osteoporosis treatment post menopausal | CCG | In tariff | Not commissioned | N/A | No | TAG | Hospital only prescribing (Red) | |
| Ibrutinib | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | http://www.england.nhs.uk/wp-content/uploads/2015/07/NCDF-list-May-2015_ver4-4-final.pdf |
| Icatibant | Hereditary angiodema - acute treatment only | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | As per policy http://www.england.nhs.uk/wp-content/uploads/2013/04/b09-p-b.pdf |
| Idarubicin | Chemotherapy in line with Network regimens | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Idelalisib | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | http://www.england.nhs.uk/wp-content/uploads/2015/07/NCDF-list-May-2015_ver4-4-final.pdf |
| Idursulfase | Mucopolysaccharidosis | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Highly specialised criteria only | Highly specialised database |
| Iloprost | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | As per policy |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------------------------|--|--------------|-------------------------------|----------------------------------|--|--|---|---|---|
| Imatinib | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA70, TA86, TA251, TA 326 or CDF policy | Hospital only prescribing (Red) | NICE & CDF audit |
| Imatinib | Graft versus host disease | NHS England | Non tariff | Not for primary care prescribing | No | No | Not routinely commissioned | Not routinely commissioned | |
| Imiglucerase | Gaucher's disease | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Highly specialised criteria only | Highly specialised database |
| Indacaterol | COPD | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Indacaterol / Glycopyrronium | COPD | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Indinavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Infertility treatment | Sub fertility | CCG | In tariff | Not for primary care prescribing | N/A | No | NICE in progress | Hospital only prescribing (Red) | |
| Infliximab or licensed biosimilar | Rheumatoid arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA130 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA130 |
| Infliximab or licensed biosimilar | Psoriasis (adults) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA134 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA134 |
| Infliximab or licensed biosimilar | Ankylosing spondylitis | CCG | Not commissioned | Not commissioned | N/A | No | TA143 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA143 |
| Infliximab or licensed biosimilar | Axial spondyloarthritis (non-radiographic) | CCG | Not commissioned | Not commissioned | N/A | No | NICE in progress | Not recommended for use (Double Red) | |
| Infliximab or licensed biosimilar | Ulcerative colitis (acute exacerbation) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA163 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA163 |
| Infliximab or licensed biosimilar | Ulcerative colitis (moderate to severe) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA329 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/ta329 |
| Infliximab or licensed biosimilar | Crohns | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA187 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA187 |
| Infliximab or licensed biosimilar | Rheumatoid arthritis (after failure of anti-TNF) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA195 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA195 |
| Infliximab or licensed biosimilar | Psoriatic arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA199 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA199 |
| Infliximab or licensed biosimilar | Connective tissue disease - interstitial lung disease | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Infliximab or licensed biosimilar | Renal | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------------------------|---|--------------|-------------------------------|----------------------------------|--|--|--|---|---|
| Infliximab or licensed biosimilar | Sarcoidosis | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Infliximab or licensed biosimilar | Graft versus host disease | NHS England | Non tariff | Not for primary care prescribing | No | No | Not routinely commissioned | Not routinely commissioned | |
| Infliximab or licensed biosimilar | Hidradenitis Suppurativa | NHS England | Non tariff | Not for primary care prescribing | No | No | Not routinely commissioned - policy in progress | Not routinely commissioned - policy in progress | |
| Infliximab or licensed biosimilar | Uveitis | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Infliximab or licensed biosimilar | Crohn's disease in children | NHS England | Non tariff | Not for primary care prescribing | | No | TA187 | Hospital only prescribing (Red) | NICE audit |
| Infliximab or licensed biosimilar | Paediatric indications (where adult TA available) | NHS England | Non tariff | Not for primary care prescribing | | No | As per Adult TA's (TA130, TA134, TA140, TA143, TA163, TA199) | Hospital only prescribing (Red) | NICE audit |
| Infliximab or licensed biosimilar | Behcet's | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | |
| Influenza (Intradermal) | Influenza prophylaxis | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Intanza |
| Inhaled corticosteroids | Children with wheeze and a cold | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | NICE NG9 |
| Inhaler devices | Childhood asthma | CCG | In tariff | Commissioned | N/A | No | TA38 & TA10 | Hospital & GP Prescribing (Double Green) | |
| Inositol nicotinate | Peripheral Arterial Disease | CCG | Not commissioned | Not commissioned | N/A | No | TA225 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA225 |
| Insulin Degludec | Type 2 Diabetes | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | PAC policy |
| Insulin Detemir | Diabetes in adults (licensed) & children (not licensed <18 yrs) | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Insulin Glargine | Diabetes | CCG | In tariff | Commissioned | N/A | No | TA53 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA53 |
| Insulin Glulisine | Diabetes | CCG | In tariff | Commissioned | N/A | No | CG87 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/CG87 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---------------------------------------|---|--------------|--|----------------------------------|--|--|--|---|---|
| Insulin Pumps | Type 1 Diabetes Adults & Children | CCG | CCG Commissioned according to regional framework. Notification | Not for primary care prescribing | N/A | No | TA151 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA151 |
| Interferon alfa | Hepatitis B and C | NHS England | Non tariff | Not for primary care prescribing | | No | TA75 | Hospital only prescribing (Red) | NICE audit |
| Interferon alfa | Adjunct to surgery in malignant melanoma | NHS England | Non tariff | Not commissioned | No | No | | Not recommended for use (Double Red) | |
| Interferon alfa | Chronic myelogenous leukaemia | NHS England | Non tariff | Not for primary care prescribing | Yes | No | | Hospital only prescribing (Red) | |
| Interferon beta 1a & 1b | Multiple sclerosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA32 & NHS England Policy | Funded DH risk sharing scheme Hospital Only | NHS E policy |
| Intratect | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Intrauterine progesterone only system | Contraception, primary menorrhagia | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Ipilimumab | Unresectable or metastatic Melanoma | NHS England | Non tariff | Not for primary care prescribing | | No | TA319 | Hospital only prescribing (Red) | https://www.nice.org.uk/Guidance/TA319 |
| Ipilimumab | Melanoma | NHS England | Non tariff | Not for primary care prescribing | | No | TA268 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA268 |
| Irinotecan | Colorectal cancer 2nd line | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Isotretinoin | Acne | CCG | In tariff | Not commissioned | N/A | No | TAG | Hospital only prescribing (Red) | |
| Ivabradine | Chronic heart failure | CCG | In tariff | Commissioned | N/A | No | TA267 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA267 |
| Ivabradine | Chronic stable angina when betablockers are contra-indicated or not tolerated | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Ivacaftor | Cystic fibrosis | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | As per policy |
| Ketoprofen & Omeprazole | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---------------------------|--|--------------|-------------------------------|--|--|--|--|---|---|
| Kiovig | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Lacosamide | Adjunctive treatment epilepsy | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Lacosamide | Epilepsy | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Lamivudine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Lamivudine | Hepatitis B | NHS England | Non tariff | Not for primary care prescribing | | No | TA96 & CG165 | Hospital only prescribing (Red) | |
| Lamivudine and zidovudine | HIV infection | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Lamivudine with Abacavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Lamotrigine | Bipolar disorder | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Lanreotide | Acromegaly | NHS England | Non tariff | Not for primary care prescribing | | No | Specialist centres only | Hospital only prescribing (Red) | Product with lowest procurement cost to be used |
| Lanreotide | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Product with lowest procurement cost to be used |
| Lanthanum | Renal dialysis only | NHS England | Non tariff | Primary care prescribing recharged to Commissioner | Yes | No | Trust Guidelines | Hospital only prescribing (Red) | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |
| Laquinimod | Multiple sclerosis | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Laronidase | Mucopolysaccharidosis | NHS England | Non tariff | Not for primary care prescribing | NHS England Service Specification | No | | Hospital only prescribing (Red) | Highly specialised database |
| Leflunomide | Psoriatic and rheumatoid arthritis | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------------------------|--|--------------------|-------------------------------|----------------------------------|--|--|-----------------------------|---|---|
| Lenalidomide | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | | No | TA171 & CDF policy | Hospital only prescribing (Red) | NICE & CDF audit http://www.england.nhs.uk/wp-content/uploads/2015/07/NCDF-list-May-2015_ver4-4-final.pdf |
| Lenalidomide | Myelodysplastic syndrome associated with isolated 5q deletion | NHS England | Non tariff | Not for primary care prescribing | | No | TA322 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/ta322 |
| Lenograstim | Barth Syndrome | NHS England | Non tariff | Not for primary care prescribing | | No | Highly specialised criteria | Hospital only prescribing (Red) | Highly specialised criteria |
| Lenograstim | Neutropenia | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy Product with lowest acquisition cost to be used |
| Letrozole | Early oestrogen-receptor+ve breast cancer post-menopausal | CCG | In tariff | Commissioned | N/A | No | TA112 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA112 |
| Leuprorelin | All other indications | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | Shared care via Hospital letter |
| Leuprorelin | Endometriosis, pre-operative management uterine fibroids | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | Shared care via Hospital letter |
| Levocardinine | 1 and 2 secondary carnitine deficiency | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Levocetirizine | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Levofloxacin Soution for Inhalation | Chronic pulmonary infections due to Pseudomonas aeruginosa in adults with CF | NHS England | Non tariff | Not commissioned | No | No | | Not recommended for use (Double Red) | Not yet licensed. NHS E commissioning. Only excluded when given by inhalation |
| Levonorgestrel 1500mcg | Emergency contraception | PH Commissioned | In tariff | Commissioned | | No | TAG | Hospital & GP Prescribing (Double Green) | Requires recharge to PH if prescribed in primary care |
| Lidocaine (Topical) | Neuropathic pain | CCG | Not commissioned | Not commissioned | N/A | No | CG96 | NICE DO NOT DO | NICE Do not Do |
| Lidocaine patches | Pain relief | CCG | Under review | Under review | N/A | No | TAG | Under review | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------------|--|--------------|-------------------------------|---|--|--|----------------------------|---|---|
| Linacotide | Irritable bowel syndrome with constipation (IBS-C) | CCG | In tariff | Commissioned according to local pathway | N/A | No | CG61 | Hospital & GP Prescribing (Double Green) | |
| Linezolid | Pneumonia, complex soft tissue infections | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Liraglutide | Indications other than T2DM and 1.8mg strength | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Liraglutide 1.2mg | Type 2 diabetes | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA203 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA203 |
| Lisdexamfetamine | ADHD in children 6 to 17 yrs | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Lithium | Bipolar disorder | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | TDM database registration |
| Lixivaptan | Hyponatraemia and other endocrine uses | NHS England | Non tariff | Not for primary care prescribing | No | No | As per IFR approval | Not routinely commissioned | |
| Lixsenatide | Type 2 Diabetes | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA203 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA203 |
| Lomustine | Anglia Cancer Network Commissioned Therapies | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Lopinavir with Ritonavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Loxapine inhalation | Schizophrenia or bipolar | CCG | Not commissioned | Not commissioned | N/A | No | TA286 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA286 |
| Lubiprostone | Chronic idiopathic constipation | CCG | In tariff | Commissioned | N/A | No | TA318 & local pathway | Hospital & GP Prescribing (Double Green) | https://www.nice.org.uk/Guidance/TA318 |
| Macitentan | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Malaria prophylaxis treatments | | Uncertain | Not commissioned | Not commissioned | N/A | No | Not on NHS prescription | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Mannitol | Cystic fibrosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA266 | Hospital only prescribing (Red) | NICE Audit & NHS E policy. Only excluded when administered by inhalation |
| Mannitol | All other indications | NHS England | Non tariff | Not for primary care prescribing | No | No | | Not recommended for use (Double Red) | |
| Maraviroc | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|--|-----------------|-------------------------------|--|--|--|-----------------------------------|---|--|
| Mecasermin | Growth Failure | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | As per policy http://www.england.nhs.uk/wp-content/uploads/2013/04/e03-p-a.pdf |
| Melatonin 2mg MR Tablets | Short term insomnia in adults | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Melatonin 2mg MR Tablets | Sleep disorders in children with ADHD | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Melatonin standard release | Any indication | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Meloxicam | Osteoarthritis | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Melphalan | Anglia Cancer Network Commissioned Therapies | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Memantine | Alzheimer's disease | CCG | In tariff | Commissioned | N/A | Yes | TA217 | Shared care available (Amber) | http://guidance.nice.org.uk/TA217 |
| Mercaptamine | Nephropathic cystinosis | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Highly specialised criteria only | Highly specialised database |
| Mercaptopurine | Steroid sparing UC/Crohns | CCG | In tariff | Commissioned according to local pathway | N/A | Yes | TAG | Shared care available (Amber) | |
| Mercaptopurine | Chemotherapy in line with Network regimens | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Mesenchymal stem cells (e.g. Prochymal®) | Acute GvHD and other indications (BCSH) | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | Hospital only prescribing (Red) | As per IFR approval |
| Methadone | Substance dependence | PH Commissioned | In tariff | Primary care prescribing recharged to Commissioner | Yes | Yes | TA114 | Shared care available (Amber) | http://guidance.nice.org.uk/TA114 |
| Methotrexate | Chemotherapy in line with Network regimens | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Methotrexate (oral & SC) | Psoriasis, IBD, RA | CCG | In tariff | Commissioned according to local pathway | N/A | Yes | CG79 | Shared care available (Amber) | http://guidance.nice.org.uk/CG79 |
| Methylnaltrexone | Opioid induced bowel dysfunction | CCG | In tariff | Not commissioned | N/A | No | TA277 | NICE not recommended | http://guidance.nice.org.uk/TA277 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|------------------------------|--|--------------|-------------------------------|---|--|--|--------------------------------|---|---|
| Methylphenidate | ADHD Children & Adolescents | CCG | In tariff | Commissioned | N/A | Yes | TA98 | Shared care available (Amber) | http://guidance.nice.org.uk/TA98 |
| Methylphenidate | ME | Uncertain | In tariff | Not commissioned | N/A | No | CG53 | NICE DO NOT DO | |
| Micafungin | Systemic fungal infections | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines & NHSE policy | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy |
| Mifamurtide | Osteosarcoma | NHS England | Non tariff | Not for primary care prescribing | | No | TA235 | Hospital only prescribing (Red) | |
| Miglustat | Gaucher's disease/ Niemann-Pick/Fabry's Disease | NHS England | Non tariff | Not for primary care prescribing | NHS England Service Specification | No | Highly specialised criteria | Hospital only prescribing (Red) | Highly specialised database |
| Minocycline | | CCG | In tariff | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Mirabegron | Overactive bladder in women | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA290 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA290 |
| Mitotane | Adrenocortical carcinoma | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Modafinil | Narcolepsy | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Monoamine oxidase inhibitors | ME | Uncertain | In tariff | Not commissioned | N/A | No | CG53 | NICE DO NOT DO | |
| Montelukast | Asthma | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Motavizumab | RSV prophylaxis | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Motavizumab | Hepatitis B | NHS England | Non tariff | Not commissioned | No | No | | Not recommended for use (Double Red) | |
| Moxifloxacin | Resistant TB patients exempt from charges | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Moxifloxacin | Respiratory infection | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Mucolytics | Prevention of exacerbations in stable COPD | CCG | In tariff | Not commissioned | N/A | No | CG101 | NICE DO NOT DO | |
| Mycophenolate | Dermatology | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|------------------------------|--|------------------------------|-------------------------------|--|--|--|--|---|---|
| Mycophenolate mofetil | Transplant immunosuppression | NHS England | Non tariff | Primary care prescribing recharged to Commissioner | Yes | No | Shared care to continue until formal repatriation agreed | See notes | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |
| Mycophenolic acid | Transplant immunosuppression | NHS England | Non tariff | Primary care prescribing recharged to Commissioner | Yes | No | Shared care to continue until formal repatriation agreed | See notes | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |
| N-acetylcysteine | Idiopathic pulmonary fibrosis | CCG | Not commissioned | Not commissioned | N/A | No | CG101 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/CG101 |
| Naftidrofuryl | Peripheral Arterial Disease | CCG | In tariff | Commissioned | N/A | No | TA223 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA223 |
| Nalmefene | Reducing alcohol consumption in people with dependence | PH Commissioned | In tariff | Under review | | No | TA325 | Under review | https://www.nice.org.uk/guidance/ta325 |
| Naltrexone | Opiate dependence | CCG | In tariff | Not for primary care prescribing | N/A | No | TA115 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA115 |
| Naltrexone | Low dose (unlicensed) | Uncertain | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Naltrexone | Alcohol use disorder - maintenance of abstinence | PH Commissioned under review | In tariff | Not for primary care prescribing | Yes | No | TAG | Not recommended for use (Double Red) | |
| Natalizumab | Multiple sclerosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA127 & NHS England Policy: D04/P/a | Hospital only prescribing (Red) | NICE Audit & NHS E policy |
| Nelarabine | CDF | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Nelfinavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Nevirapine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Nicotine replacement therapy | Smoking cessation | PH Commissioned | In tariff | Primary care prescribing recharged to Commissioner | | | PH45 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/PH45 |
| Nicotinic acid & derivatives | All indications | CCG | Not commissioned | Not commissioned | N/A | No | CG67 | NICE DO NOT DO | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------------|--|--------------------------|--------------------------------------|----------------------------------|--|--|--|---|---|
| Nilotinib | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA241 & TA251 | Hospital only prescribing (Red) | NICE audit |
| Nitisinone | Tyrosinaemia | NHS England | Non tariff | Not for primary care prescribing | NHS England Service Specification | No | Highly specialised criteria | Hospital only prescribing (Red) | Highly specialised database |
| Nitric Oxide | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | |
| Normal Immunoglobulin | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Occulsive dressings | Eczema in children | CCG | Not commissioned | Not commissioned | | | CG57 | NICE DO NOT DO | |
| Ocriplasmin | Vitreomacular traction | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA297 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA297 |
| Ocriplasmin | Vitreomacular traction with ERM | CCG | Not commissioned | Not commissioned | N/A | No | TA297 | NICE DO NOT DO | |
| Octagam | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Octreotide | Acromegaly | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | Product with lowest procurement cost to be used |
| Octreotide | Congenital hyperinsulinism | NHS England | Non tariff | Not for primary care prescribing | | No | Highly specialised criteria | Highly specialised criteria only | Highly specialised database |
| Octreotide | Chemotherapy in line with Network regimens | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | Product with lowest procurement cost to be used |
| Octreotide | Reducing vomiting in bowel obstruction | NHS England | Non tariff | Not for primary care prescribing | | No | | Under review | |
| Ofatumumab | CDF | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Olanzapine | Bipolar disorder | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Olanzapine | Schizophrenia | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Omalizumab | Chronic spontaneous urticaria | NHS England under review | Under review | Not for primary care prescribing | | No | | Under review | Under review |
| Omalizumab | Asthma | NHS England | Non tariff | Not for primary care prescribing | | No | TA278 | Hospital only prescribing (Red) | NICE audit |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------------------|--|------------------------|-------------------------------|----------------------------------|--|--|-----------------------------------|---|---|
| Omega 3 Fish oil | All indications | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Ondansetron & other 5HT3 antagonists | Nausea & vomiting | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Orlistat | Obesity | PH Commissioned | In tariff | Commissioned | | | TAG | Hospital & GP Prescribing (Double Green) | Requires recharge to PH if prescribed in primary care |
| Oseltamavir | Treatment & prophylaxis influenza | CCG | In tariff | Commissioned | N/A | No | TA169 | Hospital & GP Prescribing (Double Green) | |
| Oxaliplatin | Colon cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA100 | Hospital only prescribing (Red) | |
| Oxcarbazepine | Epilepsy | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Oxycodone & Naloxone | Pain relief | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Oxygen therapy | Indications specified in regional contract | Regional contract only | | Regional contract only | | No | | Regional contract only | |
| Paclitaxel | Early node positive breast cancer | NHS England | Non tariff | Not commissioned | No | No | TA108 | Not recommended for use (Double Red) | |
| Paclitaxel | Lymph node positive breast cancer | NHS England | Non tariff | Not commissioned | No | No | | Not recommended for use (Double Red) | |
| Paclitaxel | Metastatic breast cancer monotherapy | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Paclitaxel | NSCLC | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Paclitaxel | Ovarian cancer (advanced) | NHS England | Non tariff | Not for primary care prescribing | | No | TA91 | Hospital only prescribing (Red) | |
| Paclitaxel (albumin bound) | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | | CDF | http://www.england.nhs.uk/wp-content/uploads/2015/07/NCDF-list-May-2015_ver4-4-final.pdf |
| Palivizumab | RSV prophylaxis | NHS England | Non tariff | Not for primary care prescribing | | No | JCVI Guidelines PHE specification | Hospital only prescribing (Red) | |
| Panitumumab | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | Hospital only prescribing (Red) | http://www.england.nhs.uk/wp-content/uploads/2015/07/NCDF-list-May-2015_ver4-4-final.pdf |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---------------------------------|--|--------------------|-------------------------------|----------------------------------|--|--|---|---|---|
| Parathyroid hormone | Specialist endocrinology conditions | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Trust Guidelines | |
| Parenteral Nutrition | Intestinal failure; inadequate/ unsafe enteral feeding | NHS England | Non tariff | Not for primary care prescribing | | No | Only when duration of PN is > 14 days or initiated prior to admission. Adults; see also CG32. See also 'Manual for prescribed specialised services' | Trust Guidelines | |
| Paroxetine | Depression in children and young people | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Pasireotide | Cushing's Disease | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Pazopanib | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA215 or CDF policy | Hospital only prescribing (Red) | NICE & CDF audit |
| Peg interferon alfa | Hepatitis B and C | NHS England | Non tariff | Not for primary care prescribing | | No | TA75, TA96, TA106, TA200, TA300 CG165 | Hospital only prescribing (Red) | NICE audit |
| Pegaptanib | wet AMD | CCG | Not commissioned | Not commissioned | N/A | No | TA155 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA155 |
| Pegfilgrastim | Neutropenia | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | Hospital only prescribing (Red) | As per IFR approval |
| Pegloticase | Gout | NHS England | Non tariff | Not commissioned | No | No | TA291 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA291 |
| Pegvisomant | Acromegaly | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned - policy in progress | Hospital only prescribing (Red) | As per IFR approval |
| Pegylated liposomal doxorubicin | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | No | No | TA91 or CDF policy | NICE CDF | NICE & CDF audit |
| Pemetrexed | Maintenance Treatment NSCLC | NHS England | Non tariff | Not for primary care prescribing | No | No | TA309 | Not recommended for use (Double Red) | NICE Do not Do |
| Pemetrexed | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | No | No | TA135, TA181, TA190 or CDF policy | NICE CDF | NICE & CDF audit |
| Pentoxifylline | Peripheral Arterial Disease | CCG | Not commissioned | Not commissioned | N/A | No | TA224 | NICE not recommended | http://guidance.nice.org.uk/TA224 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|-------------------------------|--------------|-------------------------------|---|--|--|--------------------------------|---|---|
| Peptide receptor radionucleotide therapy | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Perampanel | Epilepsy | CCG | In tariff | Not for primary care prescribing | N/A | Yes | TAG | Shared care available (Amber) | |
| Perindopril arginine | | CCG | Not commissioned | Not commissioned | N/A | No | TAF | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Pertuzumab | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Pharmalgen | Venom anaphylaxis | CCG | In tariff | Not for primary care prescribing | N/A | No | TA246 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA246 |
| Pimecrolimus | Atopic eczema first line | CCG | Not commissioned | Not commissioned | N/A | No | CG57 | NICE DO NOT DO | |
| Pimecrolimus | Second line atopic eczema | CCG | In tariff | Commissioned according to local pathway | N/A | No | TA82 | GP Prescribing at request of Specialist (Green) | |
| Pioglitazone | Diabetes | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Pirfenidone | Idiopathic pulmonary fibrosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA282 (specialist centre only) | Hospital only prescribing (Red) | NICE audit |
| Pixantrone | Non Hodgkins Lymphoma | NHS England | Non tariff | Not for primary care prescribing | | No | TA 306 | Hospital only prescribing (Red) | NICE audit |
| Plerixafor | Stem cell mobilisation | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | Number of patients treated Number of patients successfully transplanted Stage drug utilised |
| Pomalidomide | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Ponatinib | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Poractant alfa | Respiratory distress syndrome | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Trust Guidelines | Product with lowest procurement cost to be used |
| Porcine Factor | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | BCSH Guidelines |
| Posaconazole | Fungal infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines & NHSE policy | Hospital only prescribing (Red) | Number of patients treated Proportion given for SPC indications within policy |
| Pramipexole immediate release | Parkinson's Disease | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------------------|---|--------------|-------------------------------|---|--|--|--|--|---|
| Pramipexole prolonged Release | Parkinson's Disease | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Prasugrel | ACS | CCG | In tariff | Commissioned | N/A | Yes | TA317 | Consultant initiates script for continuation by GP (Green) | https://www.nice.org.uk/Guidance/TA317 |
| Prasugrel | Targeted use in diabetics with ACS with aspirin | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Pregabalin | Neuropathic pain | CCG | In tariff | Commissioned according to local pathway | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Pregabalin | Generalised Anxiety Disorder | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Primatene Mist | All indications | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Privigen | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | National Guidelines | Quality dashboard |
| Probiotics | All indications | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Procarbazine | All indications | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Progestogens (oral) | Luteal phase for heavy menstrual bleeding | CCG | Not commissioned | Not commissioned | N/A | No | CG44 | NICE DO NOT DO | |
| Protein C | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | BCSH Guidelines |
| Protein kinase inhibitors | Endocrinology; non-malignant conditions | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Prothrombin Complex | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | BCSH Guidelines |
| Proton Pump Inhibitors | Dyspepsia | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Prucalopride | Chronic constipation in women | CCG | In tariff | Commissioned | N/A | No | TA211 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA211 |
| Qlaira | Contraception | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Quetiapine | Schizophrenia | CCG | In tariff | Commissioned | N/A | Yes | CG82 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/CG82 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-----------------------|---|--------------|--------------------------------------|----------------------------------|--|--|---------------------|---|--|
| Quetiapine | Severe depression with bipolar | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | |
| Quetiapine | Generalised anxiety disorder | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | |
| Radium 223 Dichloride | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Ralitrexed | Colorectal cancer | NHS England | Non tariff | Not commissioned | No | No | | Not recommended for use (Double Red) | |
| Raloxifene | Primary & Secondary prevention osteoporotic fragility fractures in postmenopausal women | CCG | In tariff | Commissioned | N/A | No | TA161 & TA160 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA161 http://www.nice.org.uk/guidance/TA160 |
| Raltegravir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | Hospital only prescribing (Red) | HARS dataset |
| Ranibizumab | Neovascular (wet) age-related macular degeneration | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA155 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA155 |
| Ranibizumab | Diabetic Macular Oedema | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA274 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/TA274 |
| Ranibizumab | Macular oedema (retinal vein occlusion) | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA283 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA283 |
| Ranibizumab | CNV due to pathological myopia | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA298 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA298 |
| Ranolazine | Adjunctive use in stable angina | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Rasagiline | Parkinson's Disease | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Rasburicase | Hyperuricaemia | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Hospital only prescribing (Red) | |
| Regorafenib | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Retigabine | Epilepsy | CCG | Not commissioned | Not for primary care prescribing | N/A | No | TA232 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA232 |
| Retinoids | Licensed indications | CCG | In tariff | Not for primary care prescribing | N/A | No | CG153 | Hospital only prescribing (Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|----------------------------------|---|--------------|-------------------------------|----------------------------------|--|--|---|---|--|
| Ribavirin | Hepatitis C | NHS England | Non tariff | Not for primary care prescribing | | No | TA75, TA106, TA200, TA300 | Hospital only prescribing (Red) | NICE audit Product with lowest procurement cost to be used |
| Rifaximin | Traveller's diarrhoea | CCG | Not commissioned | Not for primary care prescribing | N/A | No | TAG | Not recommended for use (Double Red) | |
| Rifaximin | Secondary hepatic encephalopathy | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Rilonacept | Cryopyrin-associated periodic syndrome | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Rilpivirine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Riluzole | ALS form of Motor Neurone Disease | CCG | Under review | Commissioned | N/A | No | TA20 | Shared care available (Amber) | Product with lowest procurement cost to be used |
| Riociguat | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Risedronate | Primary & Secondary prevention osteoporotic fragility fractures in postmenopausal women | CCG | In tariff | Commissioned | N/A | No | TA161 & TA160 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA161 http://www.nice.org.uk/guidance/TA160 |
| Risperidone | Schizophrenia | CCG | In tariff | Commissioned | N/A | Yes | CG82 | Shared care available (Amber) | http://guidance.nice.org.uk/CG82 |
| Risperidone | Unresponsive conduct disorder ADHD | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Risperidone depot | Schizophrenia | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Ritonavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Rituximab or licensed biosimilar | Rheumatoid arthritis (after failure of DMARDs and anti-TNF) | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA195 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA195 |
| Rituximab or licensed biosimilar | Connective tissue disease - interstitial lung disease | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned - policy in progress | As per IFR approval | As per IFR approval |
| Rituximab or licensed biosimilar | Haemophilia | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Rituximab or licensed biosimilar | Nephritis | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------------------------|---|--------------|-------------------------------|----------------------------------|--|--|---|---|---|
| Rituximab or licensed biosimilar | ANCA-positive vasculitis | NHS England | Non tariff | Not for primary care prescribing | | No | TA308 & NHS England Policy | Hospital only prescribing (Red) | NHS E policy |
| Rituximab or licensed biosimilar | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | NICE TA65, TA137, TA174, TA193, TA226, TA243; & CDF | Hospital only prescribing (Red) | NICE audit |
| Rituximab or licensed biosimilar | Graft versus host disease | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Rituximab or licensed biosimilar | Myositis | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Rituximab or licensed biosimilar | Paediatric indications (where adult TA available) | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy and NICE TA's (TA195) | Hospital only prescribing (Red) | |
| Rituximab or licensed biosimilar | Neuromyelitis optica | NHS England | Non tariff | Not for primary care prescribing | Not routinely commissioned | No | As per IFR approval | As per IFR approval | As per IFR approval |
| Rituximab or licensed biosimilar | SLE | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | |
| Rituximab Sub cutaneous formulation | Cancer | NHS England | Non tariff | Not for primary care prescribing | No | No | Not routinely commissioned | Not routinely commissioned | |
| Rivaroxaban | VTE prevention hip or knee surgery | CCG | In tariff | Not for primary care prescribing | N/A | No | TA170 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA170 |
| Rivaroxaban | Stroke & systemic embolism prevention in non-valvular AF | CCG | In tariff | Under review | N/A | No | TA256 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA256 |
| Rivaroxaban | VTE treatment and long term secondary prevention | CCG | In tariff | Under review | N/A | No | TA261 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA261 |
| Rivaroxaban | Pulmonary Embolism - Treatment & prevention recurrent VTE | CCG | In tariff | Under review | N/A | No | TA287 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA287 |
| Rivaroxaban | ACS | CCG | In tariff | Under review | N/A | No | | Under review | |
| Rivastigmine | Alzheimer's disease | CCG | In tariff | Commissioned | N/A | Yes | TA217 | Shared care available (Amber) | http://guidance.nice.org.uk/TA217 |
| Rivastigmine | Mild to moderate dementia in Parkinson's disease | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Roflumilast | COPD (unless part of agreed trial) | CCG | Not commissioned | Not commissioned | N/A | No | TA244 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA244 |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|----------------------------------|--|--------------|-------------------------------|--|--|--|--|---|---|
| Romiplostim | Chronic immune or idiopathic thrombocytopenic purpura | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA221 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA221 |
| Ropinirole | Parkinson's Disease | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Rotigotine | Parkinson's Disease | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Rubifaciants | Osteoarthritis | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | NICE Do not Do |
| Ruxolitinib | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | CDF national audit |
| Safety needles | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Saliva substitute | Xerostomia from any cause | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Salmeterol & Fluticasone inhaler | Asthma or COPD | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | Product with lowest procurement cost to be used |
| Sandoglobulin | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Sapropterin | Phenylalanine restriction | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | Highly specialised database. NHS E policy http://www.england.nhs.uk/wp-content/uploads/2013/04/e12-p-a.pdf |
| Saquinavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Second line DMARDs | Rheumatoid Arthritis | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Sevelamer | Renal dialysis only | NHS England | Non tariff | Primary care prescribing recharged to Commissioner | Yes | No | Trust Guidelines | Hospital only prescribing (Red) | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|---------------------------------------|--------------|-------------------------------|--|--|--|--|---|---|
| Sildenafil | Erectile dysfunction | CCG | In tariff | Commissioned | N/A | No | Product with lowest procurement cost to be used | Hospital & GP Prescribing (Double Green) | http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012086.pdf |
| Sildenafil | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | As per policy http://www.england.nhs.uk/wp-content/uploads/2013/04/a11-p-a.pdf Product with lowest procurement cost to be used |
| Simeprevir | Hepatitis C | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Sipuleucel-T | Cancer | NHS England | Non tariff | Not for primary care prescribing | No | No | Not routinely commissioned | Not recommended for use (Double Red) | |
| Sirolimus (Rapamycin) | Lymphangioliomyomatosis (LAM) | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Sirolimus (Rapamycin) | Transplant immunosuppression | NHS England | Non tariff | Primary care prescribing recharged to Commissioner | Yes | No | Shared care to continue until formal repatriation agreed | See notes | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |
| SIRT with yttrium-90 microspheres (NOT A DRUG) | All indications | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | | |
| Sitagliptin | Type 2 Diabetes | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Sodium Chloride (Hypertonic) | Cystic Fibrosis | NHS England | In tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Sodium Clodronate | Bone pain (mets) | Uncertain | In tariff | Under review | N/A | No | TAG | Under review | |
| Sodium Fluoride Toothpaste | | CCG | Not commissioned | Not commissioned | N/A | No | Prescribing by Dentists only | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Sodium Oxybate | Narcolepsy - paediatric patients only | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Sodium Phenylbutyrate | Urea cycle disorder | NHS England | Non tariff | Not for primary care prescribing | NHS England Service Specification | No | Highly specialised criteria | Hospital only prescribing (Red) | Highly specialised database |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|----------------------|---|--------------------|-------------------------------|----------------------------------|--|--|--|---|--|
| Solifenacin | Urge incontinence | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Somatropin | Growth disturbance in children small for gestational age | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA188 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA188 |
| Somatropin | Growth Failure in children | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA188 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA188 |
| Somatropin | Adult growth hormone deficiency | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA64 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA64 |
| Somatropin | Growth hormone deficiency | CCG | Not commissioned | Not for primary care prescribing | N/A | No | | Not recommended for use (Double Red) | Local policy from 1.4.14 |
| Sorafenib | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | CDF national audit |
| SSRI antidepressants | Depression in children | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| St John's Wort | | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Statins | CVD & T2DM | CCG | In tariff | Commissioned | N/A | No | CG181 | Hospital & GP Prescribing (Double Green) | |
| Stavudine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Streptokinase | MI- thrombolysis | CCG | In tariff | Not for primary care prescribing | N/A | No | TA94 | Hospital only prescribing (Red) | |
| Strontium | Primary & Secondary prevention osteoporotic fragility fractures in postmenopausal women | CCG | In tariff | Commissioned | N/A | No | TA161 & TA160 | Hospital & GP Prescribing (Double Green) | http://guidance.nice.org.uk/TA161 http://www.nice.org.uk/guidance/TA160 |
| Subcutia | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Subgam | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Sunitinib | Cancer | NHS England or CDF | Non tariff | Not for primary care prescribing | No | No | TA169,TA179 CDF policy | NICE CDF | NICE & CDF audit |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--------------------------------------|--|--------------|-------------------------------|--|--|--|--|---|---|
| Supplements containing Beta carotene | MI Secondary prevention | Uncertain | Not commissioned | Not commissioned | N/A | No | CG48 | NICE DO NOT DO | |
| Tacrolimus | Ulcerative colitis | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Tacrolimus | Transplant immunosuppression | NHS England | Non tariff | Primary care prescribing recharged to Commissioner | Yes | No | Shared care to continue until formal repatriation agreed | Trust Guidelines | Until formal repatriation agreed. Product with lowest procurement cost to be used. CCG reimbursement until repatriation |
| Tacrolimus ointment | Atopic eczema first line | CCG | Not commissioned | Not commissioned | N/A | No | CG57 | NICE DO NOT DO | |
| Tacrolimus ointment | Second line moderate to severe atopic eczema | CCG | In tariff | Commissioned | N/A | Yes | TA82 | Shared care available (Amber) | |
| Tadalafil | BPH | CCG | Not commissioned | Not commissioned | N/A | No | TA273 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA273 |
| Tadalafil | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | TA291 & NHS England Policy | Hospital only prescribing (Red) | As per policy http://www.england.nhs.uk/wp-content/uploads/2013/04/a11-p-a.pdf |
| Tadalafil once daily | Erectile dysfunction (regular daily use) | CCG | Not commissioned | Not commissioned | N/A | No | | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Tafamidis | Familial amyloid polyneuropathy | NHS England | Non tariff | Not commissioned | No | No | | Not recommended for use (Double Red) | AGNSS insufficient evidence for routine commissioning in England |
| Taliglucerase alfa | Gaucher's Disease | NHS England | Non tariff | Not for primary care prescribing | NHS England Service Specification | No | Highly specialised criteria | Hospital only prescribing (Red) | Highly specialised database |
| Tapentadol immediate release | Moderate to severe pain according to pathway | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Tapentadol prolonged release | Severe chronic pain according to pathway | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Teduglutide | Short bowel syndrome | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Tegafur | Colorectal cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA61 | Hospital only prescribing (Red) | |
| Teicoplanin | IV antibiotic | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Telaprevir | Hepatitis C | NHS England | Non tariff | Not for primary care prescribing | | No | TA252 | Hospital only prescribing (Red) | NICE audit |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|---|--------------|-------------------------------|----------------------------------|--|--|------------------------------------|---|---|
| Telbivudine | Hepatitis B | NHS England | Non tariff | Not for primary care prescribing | No | No | Not routinely commissioned (TA154) | Not recommended for use (Double Red) | NICE Do not Do |
| Temozolomide | Endocrinology; non-malignant conditions | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Temsirolimus | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | CDF national audit |
| Tenofovir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | TA173 & In Progress | BHIVA Guidelines | HARS dataset |
| Tenofovir with Emtricitabine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Tenofovir with Emtricitabine and Efavirenz | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Teriflunomide | Multiple sclerosis | NHS England | Non tariff | Not for primary care prescribing | | No | TA303 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA303 |
| Teriparatide | Secondary prevention osteoporotic fragility fractures in postmenopausal women | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA161 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA161 |
| Testosterone | Androgen deficiency | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Testosterone patches | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Tetrahydrobiopterin | Phenylketonuria | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Highly specialised criteria only | Highly specialised database |
| Thalidomide | Cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA228 | NICE | NICE audit |
| Thrombin | Pseudoaneurysm | NHS England | Non tariff | Not for primary care prescribing | | No | IPG060 | | |
| Ticagrelor | ACS | CCG | In tariff | Commissioned | N/A | No | TA236 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA236 |
| Tioconazole | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |
| Tioguanine | All indications | NHS England | Non tariff | Not for primary care prescribing | | No | TAG | Hospital only prescribing (Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------|--|--------------|-------------------------------|----------------------------------|--|--|--------------------------------------|---|---|
| Tiotropium | COPD | CCG | In tariff | Commissioned | N/A | No | | Hospital & GP Prescribing (Double Green) | |
| Tipranavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Tirofiban | Prevention MI unstable angina | CCG | In tariff | Not for primary care prescribing | N/A | No | TA47 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA47 |
| Tobramycin | Cystic Fibrosis | NHS England | Non tariff | Not for primary care prescribing | Excluded when given by inhalation or nebulisation | No | TA276 & NHS England Policy: A01/PS/a | Hospital only prescribing (Red) | NICE Audit & NHS E policy |
| Tocilizumab | Rheumatoid arthritis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA247 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA247 |
| Tocilizumab | Monotherapy rheumatoid arthritis after > DMARDs and two anti-TNF antagonists | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | Local policy |
| Tocilizumab | Large vessel vasculitis | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | |
| Tocilizumab | Juvenile arthritis | NHS England | Non tariff | Not for primary care prescribing | | No | TA238 | NICE | NICE audit |
| Tocilizumab | Paediatric indications (where adult TA available) | NHS England | Non tariff | Not for primary care prescribing | | No | As per Adult TA's (TA247) | NICE | NICE audit |
| Tolvaptan | Hyponatraemia and other endocrine uses | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Topotecan | Ovarian cancer (advanced) | NHS England | Non tariff | Not for primary care prescribing | | No | TA91 | Hospital only prescribing (Red) | |
| Topotecan | Relapsed SCLC | NHS England | Non tariff | Not for primary care prescribing | | No | TA184 | Hospital only prescribing (Red) | |
| Topotecan | Stage IVB cervical cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA183 | Hospital only prescribing (Red) | |
| Trabectedin | Relapsed ovarian cancer | NHS England | Non tariff | Not commissioned | No | No | TA222 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA222 |
| Trabectedin | Soft tissue sarcoma | NHS England | Non tariff | Not for primary care prescribing | | No | TA185 | Hospital only prescribing (Red) | |
| Trastuzumab | Advanced breast cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA34 | Hospital only prescribing (Red) | |
| Trastuzumab | HER2 positive breast cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA107 | Hospital only prescribing (Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|-------------------------|--|-----------------|-------------------------------|--|--|--|---------------------|---|---|
| Trastuzumab | HER2 positive breast cancer with aromatase inhibitor | NHS England | Non tariff | Not commissioned | No | No | TA257 | Not recommended for use (Double Red) | |
| Trastuzumab | HER2 positive gastric cancer | NHS England | Non tariff | Not for primary care prescribing | | No | TA208 | Hospital only prescribing (Red) | |
| Trastuzumab Emtansine | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | CDF national audit |
| Treosulfan | All indications | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Treprostinil sodium | Pulmonary Arterial Hypertension | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Policy | Hospital only prescribing (Red) | Only if already established on treatment |
| Triptorelin | Endometriosis, pre-operative management uterine fibroids | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Triptorelin | Precocious puberty | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care available (Amber) | |
| Triptorelin | Prostate cancer | CCG | In tariff | Commissioned | N/A | Yes | TAG | Shared care via Hospital letter | |
| Turoctocog alfa | As per BCSH Guidelines | NHS England | Non tariff | Not for primary care prescribing | | No | BCSH Guidelines | Hospital only prescribing (Red) | BCSH Guidelines |
| Ulipristal | Uterine fibroids | CCG | In tariff | Not commissioned | N/A | No | TAG | Hospital only prescribing (Red) | |
| Ulipristal | Emergency contraception | PH Commissioned | In tariff | Primary care prescribing recharged to Commissioner | | | TAG | Hospital & GP Prescribing (Double Green) | Requires recharge to PH if prescribed in primary care |
| Ustekinumab | Severe plaque psoriasis | CCG | Non tariff. Subject to audit | Not for primary care prescribing | N/A | No | TA180 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA180 |
| Ustekinumab | Psoriatic arthritis | CCG | Not commissioned | Not commissioned | N/A | No | TA313 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA313 |
| Vaccum assisted devices | erectile dysfunction | CCG | Not commissioned | Not commissioned | N/A | No | PAC policy | Not recommended for use (Double Red) | |
| Vacuum dressings | | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Valganciclovir | Cytomegalovirus | NHS England | Non tariff | Not for primary care prescribing | Trust Guidelines | No | Trust Guidelines | Trust Guidelines | Number of patients treated Proportion given for SPC indications within policy |
| Vandetinib | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Vardenafil | Erectile dysfunction (regular daily use) | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | Norfolk & Waveney Drugs of Low Priority |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|--|---|-----------------|--------------------------------------|--|--|--|---|---|---|
| Varenicline | Smoking cessation | PH Commissioned | In tariff | Primary care prescribing recharged to Commissioner | | | TA123 | GP Prescribing at request of Specialist (Green) | http://guidance.nice.org.uk/TA123 |
| Various drugs for erectile dysfunction | Erectile dysfunction | CCG | In tariff | Commissioned | N/A | No | Product with lowest procurement cost to be used | Hospital & GP Prescribing (Double Green) | http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012086.pdf |
| Various drugs for erectile dysfunction | Severe distress | CCG | In tariff | Not for primary care prescribing | N/A | No | Product with lowest procurement cost to be used | Hospital only prescribing (Red) | http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012086.pdf |
| Vedolizumab | Crohn's disease | CCG | Non tariff. Subject to audit | Not commissioned | N/A | No | Under review | Under review | |
| Vedolizumab | Moderate to severe ulcerative colitis - second line | CCG | Under review | Not commissioned | N/A | No | TA342 | Hospital only prescribing (Red) | http://www.nice.org.uk/guidance/ta342 |
| Vedolizumab | Inflammatory bowel disease | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Vedolizumab | Crohn's disease in children | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned | As per IFR approval | As per IFR approval |
| Velaglucerase alfa | Gaucher's Disease | NHS England | Non tariff | Not for primary care prescribing | | No | NHS England Service Specification | Highly specialised criteria only | Highly specialised database |
| Vemurafenib | Melanoma | NHS England | Non tariff | Not for primary care prescribing | | No | TA269 | Hospital only prescribing (Red) | http://guidance.nice.org.uk/TA269 |
| Venlafaxine | Depression in children and young people | CCG | Not commissioned | Not commissioned | N/A | No | | NICE DO NOT DO | |
| Verteporfin | AMD photodynamic therapy | CCG | Non tariff. Prior approval and audit | Not for primary care prescribing | N/A | No | TA68 | Hospital only prescribing (Red) | Under review |
| Vigam | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Vildagliptin | Diabetes | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Vinflunine | Urinary tract carcinoma | NHS England | Non tariff | Not commissioned | No | No | TA272 | Not recommended for use (Double Red) | http://guidance.nice.org.uk/TA272 |
| Vinorelbine | Advanced breast cancer | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|---|--|--------------|-------------------------------|----------------------------------|--|--|---|---|--|
| Vinorelbine | NSCLC | NHS England | Non tariff | Not for primary care prescribing | | No | | Hospital only prescribing (Red) | |
| Vismodegib | Cancer | CDF | Non tariff | Not for primary care prescribing | | No | CDF policy | CDF | SACT & CDF national audit |
| Vivaglobin | As per National DMP | NHS England | Non tariff | Not for primary care prescribing | | No | Immunoglobulin clinical guidelines (July 2011) | Hospital only prescribing (Red) | Quality dashboard |
| Voriconazole | Chronic pulmonary aspergillosis | NHS England | Non tariff | Not for primary care prescribing | | No | Highly specialised criteria | Hospital only prescribing (Red) | Highly specialised criteria |
| Voriconazole | Fungal infection | NHS England | Non tariff | Not for primary care prescribing | | No | Trust Guidelines | Trust Guidelines | Number of patients treated Proportion given for SPC indications within policy |
| Warfarin | Various | CCG | In tariff | Commissioned | N/A | No | TAG | Hospital & GP Prescribing (Double Green) | |
| Yasmin | Contraception | CCG | Not commissioned | Not commissioned | N/A | No | TAG | Not recommended for use (Double Red) | |
| Zaleplon | Short term treatment insomnia | CCG | In tariff | Commissioned | N/A | No | TA77 | Hospital & GP Prescribing (Double Green) | |
| Ziconotide | Intrathecal analgesia | NHS England | Non tariff | Not for primary care prescribing | | No | Not routinely commissioned - policy in progress | As per IFR approval | As per IFR approval |
| Zidovudine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Zidovudine with Lamivudine | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Zidovudine with Lamivudine and Abacavir | HIV infection in combination with other antiretroviral drugs | NHS England | Non tariff | Not for primary care prescribing | | No | BHIVA Guidelines | BHIVA Guidelines | HARS dataset |
| Zoledronic acid | SRE in plasma cell myeloma | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |
| Zoledronic acid | Treatment of postmenopausal osteoporosis | CCG | In tariff | Not for primary care prescribing | N/A | No | TAG | Hospital only prescribing (Red) | |

Combined Commissioned Drug Therapies List

Key: Red fill - TAG Double Red / Red font - TAG Red (Hospital Only) / Green fill - TAG Double Green / Green font - TAG Green / Blue fill - SCG / Pink fill - PH

| Drug Name | Indication | Commissioner | Secondary Care Funding Status | Primary Care Funding Status | SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL | SHARED CARE BETWEEN SECONDARY AND PRIMARY CARE | Supporting Guidance | TAG classification or Prescribing Responsibility (if any) | Further information & monitoring requirements |
|------------|-------------------------------|--------------|-------------------------------|-----------------------------|--|--|---------------------|---|---|
| Zolpidem | Short term treatment insomnia | CCG | In tariff | Commissioned | N/A | No | TA77 | Hospital & GP Prescribing (Double Green) | |
| Zonisamide | Epilepsy | CCG | In tariff | Commissioned | N/A | No | TAG | GP Prescribing at request of Specialist (Green) | |
| Zopiclone | Short term treatment insomnia | CCG | In tariff | Commissioned | N/A | No | TA77 | Hospital & GP Prescribing (Double Green) | |